Guo-Liang‘ Dai

Dr. Guo-Liang‘ Dai


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2018 in RSC Advances
Verified
Journal Article
Open access
PDF file
QCQianyu Cao
Qianyu Cao
SHShengwei Hong
Shengwei Hong
YLYuanyuan Li
Yuanyuan Li
HCHeng Chen
Heng Chen
YSYining Shen
Yining Shen
GDGuo-Liang‘ Dai
Guo-Liang‘ Dai
Treating colorectal cancer (CRC) continues to be a clinical challenge. Coptisine, an alkaloid derived from Coptis chinensis Franch. shows toxic effects on CRC cells, but its underlying mechanism remains elusive. MFG-E8 is involved in tumor growth and progression. Herein, we evaluated the effects of coptisine on MFG-E8 in CRC, and explored the mechanism. The expression of MFG-E8 in CRC and adjacent normal colon tissue samples from patients was detected. The effects of coptisine on CRC cells HCT116 in vitro were evaluated by CCK-8, adhesion and transwell assays. A xenograft tumor model was used to assess the effects of coptisine in vivo. The morphology of CRC tissue was observed by HE staining. Cell signaling was tested using western blotting and immunohistochemical assay. The expression of MFG-E8 in human CRC tissue samples significantly increased compared with that of adjacent normal ones. Coptisine significantly reduced the expressions of MFG-E8 in HCT116 cells and tumor-bearing mice. Moreover, coptisine suppressed the growth, adhesion and metastasis of CRC cells. Coptisine also suppressed the expression of MMP-2 and MMP-9 via the PI3K/AKT signaling pathway. Furthermore, it inhibited epithelial–mesenchymal transition in vivo and in vitro. Coptisine inhibited CRC growth and progression by down-regulating MFG-E8, and is a potential candidate for treatment.

1 February 2013 in Complementary Therapies in Medicine
Verified
Journal Article
Closed access
SMShitang Ma
Shitang Ma
CFCheng-Tao Feng
Cheng-Tao Feng
XZXiaolin Zhang
Xiaolin Zhang
GDGuo-Liang‘ Dai
Guo-Liang‘ Dai
CLChangyin Li
Changyin Li
HYHao Yu
Hao Yu

1 July 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
XWXingxing Wu
Xingxing Wu
KLKexin Liu
Kexin Liu
QWQi Wu
Qi Wu
MWMao Wang
Mao Wang
XCXuelian Chen
Xuelian Chen
ZSZhaowei Shan
Zhaowei Shan
Aims. This study aims to investigate the potential biomarkers of inflammatory bowel disease (IBD) and IBD with damp-heat syndrome (IBD-DH) by metabolomics. Methods. Plasma and urine samples were collected from 15 healthy controls and 30 IBD patients, including 15 IBD-DH and 15 IBD with spleen deficiency syndrome (IBD-SD), which was coded as SF8G and SF70 according to the International Classification of Diseases Eleventh Revision (ICD-11) issued by World Health Organization. Pseudotargeted metabolomics method was used based on ultra-high-performance liquid chromatography-high-resolution mass spectrometry and triple-quadrupole mass spectrometry. Results. Under the condition of false discovery rate (FDR)1.0, and fold change (FC)>1.5 or<2/3, we found 57 plasma differential metabolites and 20 urinary differential metabolites in IBD. Then, with area under the curve (AUC)0.85 and FC2 or 0.3, 11 potential biomarkers were identified, such as acylcarnitine (ACar 20:4, ACar 18:1, and ACar 20:3), 3-indoleacetic acid, hippuric acid, and dehydroepiandrosterone sulfate, which is related to intestinal microbiota and immune response. However, less obvious differences were observed in IBD-DH when compared with IBD-SD. Under the condition of FDR1.0, and FC>1.5 or <2/3, we identified 16 plasma differential metabolites. In urine samples, IBD-DH and IBD-SD had the same metabolite pattern. With AUC0.80, 7 differential plasma metabolites, mainly glycerophospholipids, were identified in IBD-DH. Kyoto Encyclopedia of Genes and Genomes analysis indicated that metabolic pathways, such as citrate cycle and amino acids metabolism, were mainly responsible for the distinction between IBD and healthy controls, whereas glycerophospholipid metabolism perturbation was not only a manifestation of IBD but also an important pathway to distinguish two subtypes defined by traditional medicine, IBD-DH and IBD-SD. Conclusion. In this study, we found that several metabolites of aromatic acids and lipid derivatives could act as potential biomarkers to discriminate IBD from healthy controls. Glycerophospholipids metabolites might be used to differentiate IBD-DH from IBD-SD.

4 July 2018 in Biomedical Chromatography
Verified
Journal Article
Closed access
PDF file
GDGuo-Liang‘ Dai
Guo-Liang‘ Dai
BSBingting Sun
Bingting Sun
LWLei Wu
Lei Wu
XGXiaojun Gao
Xiaojun Gao
SSShanshan Song
Shanshan Song
WJWenzheng Ju
Wenzheng Ju

1 April 2002 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
GDGuo-Liang‘ Dai
Guo-Liang‘ Dai
JLJinru Li
Jinru Li
LJLong Jiang
Long Jiang

13 April 2022 in Chinese Journal of Integrative Medicine
Verified
Journal Article
Closed access
PDF file
TGTian-Hao Guo
Tian-Hao Guo
YLYuan-Yuan Li
Yuan-Yuan Li
SHSheng-Wei Hong
Sheng-Wei Hong
QCQian-Yu Cao
Qian-Yu Cao
HCHeng Chen
Heng Chen
GSGang Shao
Gang Shao